STOCK TITAN
  1. Home
  2. News
  3. GERN
  4. Geron to Present at the Stifel Virtual Healthcare Conference

Geron to Present at the Stifel Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

FOSTER CITY, Calif.--()--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 2:40 p.m. ET.

A live audio webcast of the presentation will be available on Geron’s website, www.geron.com/investors/events. If you are unable to listen to the live presentation, an archived webcast will be available on the Company’s website for 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

Contacts

Suzanne Messere
Investor and Media Relations
investor@geron.com
media@geron.com

Stock GERN logo
Geron Corp

NASDAQ:GERN

GERN Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

GERN Latest News

Apr 18, 2025
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 31, 2025
Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025
Mar 19, 2025
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 11, 2025
Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS
Mar 11, 2025
Geron Corporation Announces Departure of Chief Executive Officer

GERN Stock Data

885.31M
632.77M
0.1%
78.42%
9.17%
Biotechnology
Pharmaceutical Preparations
Link
United States
FOSTER CITY